

Supplemental Material

Interactions Between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease

Laura Grau, MPH¹, Berenice Gitomer, PhD¹, Bryan McNair, MS¹, Myles Wolf, MD², Peter Harris, PhD³, Godela Brosnahan, MD¹, Vicente Torres, MD³, Theodore Steinman, MD⁴, Alan Yu, MD⁵, Arlene Chapman, MD⁶, Michel Chonchol, MD¹, Kristen L Nowak, PhD, MPH¹

Table of Contents

- 1. Supplemental Table 1**
- 2. Supplemental Table 2**

Supplemental Table 1: Associations of 1,25(OH)₂D and Genotype Interactions with Risk of the Composite Endpoint (50% Decline in eGFR, ESRD or Death) in HALT-PKD Study A and B

	HR (95% CI)	
1,25(OH)₂D * Genotype Groups	Unadjusted	Adjusted
<i>PKD1</i> Non-Truncating, 1,25(OH) ₂ D Tertile 1	0.86 (0.62, 1.20)	1.01 (0.72, 1.42)
<i>PKD1</i> Non-Truncating, 1,25(OH) ₂ D Tertile 2	0.61 (0.39, 0.94)	0.95 (0.62, 1.45)
<i>PKD1</i> Non-Truncating, 1,25(OH) ₂ D Tertile 3	0.40 (0.20, 0.82)	0.88 (0.46, 1.69)
<i>PKD2</i> , 1,25(OH) ₂ D Tertile 1	0.36 (0.21, 0.61)	0.54 (0.41, 0.95)
<i>PKD2</i> , 1,25(OH) ₂ D Tertile 2	0.39 (0.21, 0.70)	0.58 (0.31, 1.11)
<i>PKD2</i> , 1,25(OH) ₂ D Tertile 3	0.42 (0.17, 1.01)	0.63 (0.24, 1.70)
NMD, 1,25(OH) ₂ D Tertile 1	0.72 (0.36, 1.43)	0.62 (0.30, 1.27)
NMD, 1,25(OH) ₂ D Tertile 2	0.78 (0.41, 1.46)	0.70 (0.36, 1.37)
NMD, 1,25(OH) ₂ D Tertile 3	0.86 (0.62, 1.20)	0.83 (0.33, 2.07)

1,25(OH)₂D, 1,25-dihydroxyvitamin D; HR, hazard ratio, 95% CI; 95% confidence interval; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; NMD, no mutation detected

Adjusted model is adjusted for age, sex, body mass index, systolic blood pressure, randomization group, calcium, phosphorus, baseline estimated glomerular filtration rate, urinary albumin excretion

1,25(OH)₂D tertile 1 is at 24.8 pg/ml; 1,25(OH)₂D tertile 2 is at 32.0 pg/ml; 1,25(OH)₂D tertile 3 is at 40.7 pg/ml

Supplemental Table 2: Associations of 25(OH)D and Genotype Interactions with Risk of the Composite Endpoint (50% Decline in eGFR, ESRD or Death) in HALT-PKD Study A and B

	Composite Endpoint	
	HR (95% CI)	
25(OH)D * Genotype Groups	Unadjusted	Adjusted
<i>PKD1</i> Non-Truncating, 25(OH)D Tertile 1	0.70 (0.47, 1.06)	1.11 (0.71, 1.75)
<i>PKD1</i> Non-Truncating, 25(OH)D Tertile 2	0.76 (0.55, 1.06)	1.04 (0.73, 1.48)
<i>PKD1</i> Non-Truncating, 25(OH)D Tertile 3	0.82 (0.58, 1.15)	0.98 (0.68, 1.41)
<i>PKD2</i> , 25(OH)D Tertile 1	0.37 (0.19, 0.74)	0.69 (0.31, 1.53)
<i>PKD2</i> , 25(OH)D Tertile 2	0.37 (0.22, 0.63)	0.58 (0.33, 1.01)
<i>PKD2</i> , 25(OH)D Tertile 3	0.37 (0.21, 0.68)	0.49 (0.25, 0.99)
NMD, 1,25(OH) ₂ D Tertile 1	0.42 (0.17, 1.04)	0.56 (0.23, 1.38)
NMD, 25(OH)D Tertile 2	0.58 (0.30, 1.10)	0.64 (0.32, 1.25)
NMD, 25(OH)D Tertile 3	0.79 (0.40, 1.54)	0.71 (0.36, 1.42)

25(OH)D, 25-hydroxyvitamin D; HR, hazard ratio, 95% CI; 95% confidence interval; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; NMD, no mutation detected

Adjusted model is adjusted for age, sex, body mass index, systolic blood pressure, randomization group, calcium, phosphorus, baseline estimated glomerular filtration rate, urinary albumin excretion

25(OH)D tertile 1 is at 25.6 ng/ml; 25(OH)D tertile 2 is at 33.9 ng/ml; tertile 3 is at 41.5 ng/ml